OncoMatch/Clinical Trials/NCT05410717
CLDN6/GPC3/Mesothelin/AXL-CAR-NK Cell Therapy for Advanced Solid Tumors
Is NCT05410717 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies Claudin6, GPC3, Mesothelin, or AXL targeting CAR-NK cells for stage iv ovarian cancer.
Treatment: Claudin6, GPC3, Mesothelin, or AXL targeting CAR-NK cells — This study is an open, exploratory clinical study to evaluate the safety and preliminary efficacy of Claudin6, GPC3, Mesothelin, or AXL targeting CAR-NK cells in patients with Claudin6, GPC3, Mesothelin, or AXL-positive advanced solid tumors (ovarian cancer and others)
Check if I qualifyExtracted eligibility criteria
Cancer type
Ovarian Cancer
Endometrial Cancer
Biomarker criteria
Required: CLDN6 expression
other cancers with expression of claudin6
Required: CLDN6 CAR expression ≥20% in autologous NK cells (≥20%)
Available autologous transduced NK cells with greater than or equal to 20% expression of Claudin6
Required: GPC3 CAR expression ≥20% in autologous NK cells (≥20%)
Available autologous transduced NK cells with greater than or equal to 20% expression of ... GPC3
Required: MSLN CAR expression ≥20% in autologous NK cells (≥20%)
Available autologous transduced NK cells with greater than or equal to 20% expression of ... Mesothelin
Required: AXL CAR expression ≥20% in autologous NK cells (≥20%)
Available autologous transduced NK cells with greater than or equal to 20% expression of ... AXL-CAR
Prior therapy
Cannot have received: gene therapy
Had accepted gene therapy before
Lab requirements
Kidney function
Liver function
Cardiac function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify